Filing summary
Issuer and period: The supplied filing is AgeX Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2023, filed March 22, 2024. Although the request identifies Serina Therapeutics, this is AgeX’s filing and reports AgeX’s standalone historical financial results, not Serina’s annual financial statements.
Business context and reporting period
AgeX was a discovery-stage biotechnology company developing aging and regenerative-medicine technologies. Its programs included stem-cell-derived candidates, induced tissue regeneration, and research products. AgeX had no approved therapeutic products and described research-product revenue as insignificant. It had reduced staffing, closed its research laboratory, and relied on university research and outside service providers.
AgeX had agreed to acquire Serina Therapeutics in a merger announced in August 2023. Both companies’ stockholders had approved the transaction by the time of the 10-K, but closing conditions remained outstanding and completion was not assured. The proposed combined company was expected to focus primarily on Serina’s pipeline. The 10-K also reports subsequent events through March 22, 2024; share figures and prices are generally adjusted for the March 14, 2024, 1-for-35.17 reverse stock split.
Key financial metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $142,000 | $34,000 |
| Gross profit | $102,000 | $21,000 |
| Research and development expense | $734,000 | $1.025 million |
| General and administrative expense | $9.328 million | $5.971 million |
| Operating loss | $9.887 million | $6.975 million |
| Other expense, net | $4.924 million | $3.547 million |
| Net loss | $14.811 million | $10.522 million |
| Net loss attributable to AgeX | $14.803 million | $10.462 million |
- Revenue included $77,000 of NIH grant revenue and $65,000 of research-product sales. The grant was awarded for up to approximately $341,000 over one year; revenue is recognized as allowable expenses are incurred.
- G&A increased 56.2%, primarily due to merger-related professional and consulting fees, a prepaid registration-cost write-off, and estimated litigation fees. R&D expense fell 28.4% as research and related spending declined.
- Interest expense, net, was $4.9 million, largely reflecting amortization of debt issuance costs and other debt-related charges.
- At December 31, 2023, cash and cash equivalents were $345,000; restricted cash was $50,000. Current assets were $754,000, current liabilities $5.914 million, total liabilities $6.607 million, and total stockholders’ equity $5.358 million. Accumulated deficit was $131.0 million.
- 2023 cash flows: $7.8 million used in operating activities, $10.0 million used in investing activities for the loan to Serina, and $17.5 million provided by financing activities, entirely from Juvenescence loan facilities. Cash, cash equivalents, and restricted cash decreased by $300,000 to $395,000.
- The balance sheet reported a $10.554 million convertible note receivable from Serina, including accrued interest. It was scheduled to mature in March 2026, but the filing says it would be canceled for no consideration if the merger closed.
Material changes, liquidity and debt
- Net loss attributable to AgeX increased to $14.803 million from $10.462 million. Revenue remained immaterial relative to operating costs; G&A rose while R&D declined.
- AgeX exchanged $36 million of Juvenescence debt for preferred stock in July 2023. Those preferred shares converted into 1,421,666 common shares on February 1, 2024, and no preferred shares remained outstanding afterward.
- As of March 20, 2024, AgeX reported approximately $8.1 million of Juvenescence borrowings and accrued origination fees outstanding. The filing identifies approximately $7.4 million due May 9, 2024, under the 2022 Secured Note and $692,800 due March 13, 2026, under the 2023 Secured Note. The 2022 note maturity had been extended to May 9, 2024.
- The loans are secured by substantially all relevant AgeX and subsidiary assets, with subsidiary guarantees. Covenants restrict additional borrowing and certain transactions. The filing describes plans for UniverXome to assume specified assets, liabilities, and Juvenescence debt in connection with the merger; the transfer and restructuring were not described as completed.
- Management and the auditor both disclosed substantial doubt about AgeX’s ability to continue as a going concern. Management said available cash and remaining borrowing capacity would not fund anticipated requirements for the twelve months after issuance of the statements, and AgeX had no other committed financing source.
Outlook, risks and unusual items
- Merger: Subject to closing conditions, Serina holders were expected to own about 75% and pre-merger AgeX holders about 25% of the combined company on a pro forma fully diluted basis, subject to assumptions and exclusions. A closing condition required at least $500,000 of immediately spendable unrestricted cash, net of specified liabilities. If the merger failed, AgeX expected to pursue its existing strategy and strategic alternatives, but warned Juvenescence might stop funding operations.
- Serina pipeline outlook: Serina was advancing SER-252 (POZ-apomorphine) through preclinical work, targeting an IND submission and Phase I trial initiation in Q4 2024. SER-227 and SER-228 were positioned for IND-enabling studies. These are stated plans, not assurances of timing or success.
- Financing and control: Juvenescence was a major stockholder and creditor, held approximately 75.6% of outstanding common shares after the preferred-stock conversion, and could materially influence AgeX before the merger. Additional financing could dilute stockholders or impose restrictive terms.
- Listing and capital structure: AgeX had faced NYSE American stockholders’ equity deficiencies and potential delisting proceedings. The reverse split may not support the share price or liquidity over time. On March 19, 2024, AgeX distributed three Post-Merger Warrants for each five shares held; each was exercisable for a unit at $13.20, with an additional Incentive Warrant exercisable at $18.00 per share.
- Development and market risks: AgeX’s candidates had not entered human clinical trials. The filing highlights clinical, regulatory, manufacturing, intellectual-property, reimbursement, and financing risks. It also warns that GLP-1 drugs could reduce the commercial opportunity for AGEX-BAT1 in obesity and type 2 diabetes.
- Unusual items and contingencies: The 2023 loss included substantial debt-cost amortization, merger expenses, and a $360,000 write-off of prepaid shelf-registration costs. A shareholder lawsuit relating to the merger was dismissed without prejudice in March 2024. The auditor issued an unmodified opinion on the financial statements but included a going-concern explanatory section.
Important facts for investors to verify
- Whether the merger closed, whether all closing conditions were met or waived, and the final ownership percentages and exchange terms.
- AgeX’s post-period cash, actual debt balances and maturities, Juvenescence funding and security arrangements, and the completion and effects of any UniverXome asset and liability transfers.
- Whether the proposed $15 million of Juvenescence warrant-exercise proceeds was received on the schedule described in the side letter.
- NYSE American listing status and the effect of the reverse split and warrant issuances on share count, dilution, and liquidity.
- Serina’s actual progress toward the stated SER-252 IND and Phase I timing, and the status of its other pipeline and partnering programs.
- The distinction between AgeX’s historical results in this 10-K and Serina’s financial condition, which this filing does not clearly provide.